Universal coverage of IVF: benefits, unintended barriers and lessons from the French model in an international perspective
Reproductive BioMedicine Online · 2026-05 · 52 (5) · 105542
DOI: 10.1016/j.rbmo.2026.105542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive BioMedicine Online, 2026-05. Verfasst von Maxime Chaillot und 7 weiteren Autor:innen. Beteiligte Einrichtung: Médecine et biologie de la reproduction, CHU Nantes, Nantes, France; Association Nationale du Don D'Engendrement (ANNDDE), Nancy, France. Hauptthemen laut MEDLINE: Fertilization in Vitro, Universal Health Insurance. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
France's universal public funding of assisted reproductive technology represents a major achievement for reproductive equity. By removing financial barriers, it has broadened access to fertility care while ensuring high standards of safety, traceability and clinical outcomes. Public oversight has further strengthened quality assurance through mandatory ISO 15189 accreditation of IVF laboratories and implementation of EU Tissues and Cells regulations. However, expanding entitlement without a proportional reinforcement of resources, staffing, laboratory capacity, reimbursement levels and donor availability has generated structural tensions. Complex regulatory demands impose substantial administrative and financial burdens on centres, diverting time and investment from patient care. Inadequate funding of IVF units, persistent shortages of gamete donors and rising overhead costs have created waiting lists and inequitable delays. France also prohibits certain internationally accepted procedures, such as preimplantation genetic testing for aneuploidies, restricting clinical autonomy and patient choice. These unintended effects risk undermining the very principles of universality, equity and quality that underpin France's policy. Comparison with Belgium, the UK, Spain and Quebec, systems that pair broad coverage with more flexible regulation or reimbursement, helps identify ways to rebalance access, oversight and innovation. We propose pragmatic policy adjustments, including realistic reimbursement of laboratory costs, streamlined accreditation, targeted donor-recruitment incentives and evidence-based reconsideration of prohibited techniques.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Médecine et biologie de la reproduction, CHU Nantes, Nantes, France; Association Nationale du Don D'Engendrement (ANNDDE), Nancy, France.
- Association Nationale du Don D'Engendrement (ANNDDE), Nancy, France; Centre AMP Nataliance, Laboratoire Mlab, Pôle Santé Oréliance, Saran, France.
- Association Nationale du Don D'Engendrement (ANNDDE), Nancy, France; Inovie Labosud, Montpellier, France.
- Biogroup fertilité, Levallois, France.
- Association Nationale du Don D'Engendrement (ANNDDE), Nancy, France; Médecine de la reproduction, CHU Nancy, Nancy, France.
- Association Nationale du Don D'Engendrement (ANNDDE), Nancy, France; Mila, Institut québécois d'intelligence artificielle, Montréal, Quebec, Canada.
Zitieren
APA
Chaillot, M., Pollet-Villard, X., Sanguinet, P., Lefleuter, N., Agopiantz, M., Bachelot, G., Brouillet, S., & Fréour, T. (2026). Universal coverage of IVF: benefits, unintended barriers and lessons from the French model in an international perspective. Reproductive BioMedicine Online, 52(5), 105542. https://doi.org/10.1016/j.rbmo.2026.105542
Vancouver
Chaillot M, Pollet-Villard X, Sanguinet P, Lefleuter N, Agopiantz M, Bachelot G, et al. Universal coverage of IVF: benefits, unintended barriers and lessons from the French model in an international perspective. Reproductive BioMedicine Online. 2026;52(5):105542. doi:10.1016/j.rbmo.2026.105542
BibTeX
@article{Chaillot2026,
author = {Chaillot, Maxime and Pollet-Villard, Xavier and Sanguinet, Pierre and Lefleuter, Nicolas and Agopiantz, Mikael and Bachelot, Guillaume and Brouillet, Sophie and Fréour, Thomas},
title = {Universal coverage of IVF: benefits, unintended barriers and lessons from the French model in an international perspective},
journal = {Reproductive BioMedicine Online},
year = {2026},
volume = {52},
number = {5},
pages = {105542},
doi = {10.1016/j.rbmo.2026.105542}
}
EUVIMED